Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated W...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Stahl, M, Bewersdorf, JP, Xie, Z, Porta, MGD, Komrokji, R, Xu, ML, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, DA, Roboz, GJ, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, RF, List, AF, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, P, Figueroa, ME, Fenaux, P, Efficace, F, DeZern, AE, Daver, NG, Churpek, JE, Carraway, HE, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, AH, Santini, V, Savona, MR, Zeidan, AM
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Elsevier 2023

Míreanna comhchosúla

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
de réir: Efficace, F, et al.
Foilsithe / Cruthaithe: (2024)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
de réir: Fabio Efficace, et al.
Foilsithe / Cruthaithe: (2024-05-01)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
de réir: Rami S. Komrokji, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Generalized GM-MDS: Polynomial Codes Are Higher Order MDS
de réir: Brakensiek, Joshua, et al.
Foilsithe / Cruthaithe: (2024)

The weights in MDS codes
de réir: Ezerman, Martianus Frederic, et al.
Foilsithe / Cruthaithe: (2019)

Construction of MDS matrices
de réir: Peng-fei LI, et al.
Foilsithe / Cruthaithe: (2016-06-01)

Application of classical Hermitian self-orthogonal MDS codes to quantum MDS codes
de réir: Jin, Lingfei, et al.
Foilsithe / Cruthaithe: (2012)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
de réir: Rafal Machowicz, et al.
Foilsithe / Cruthaithe: (2023-08-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
de réir: Loizos Petrikkos, et al.
Foilsithe / Cruthaithe: (2023-12-01)

New quantum MDS codes
de réir: Zhang, Guanghui, et al.
Foilsithe / Cruthaithe: (2015)

Inherited predisposition to MDS/AML
de réir: Ana Rio Machin, et al.
Foilsithe / Cruthaithe: (2018-06-01)

The impact of spliceosome mutations in MDS
de réir: Jacqueline Boultwood, et al.
Foilsithe / Cruthaithe: (2019-06-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
de réir: Chen, J, et al.
Foilsithe / Cruthaithe: (2022)

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
de réir: F. Schulz, et al.
Foilsithe / Cruthaithe: (2022-06-01)

MDS plus data acquisition system
de réir: Stillerman, J.A., et al.
Foilsithe / Cruthaithe: (2015)

Diffusion analysis of EFN-MDS structure
de réir: Ibrahim, Subariah
Foilsithe / Cruthaithe: (2006)

Diffusion analysis of EFN-MDS structure
de réir: Ibrahim, Subariah, et al.
Foilsithe / Cruthaithe: (2006)

The role of innate immunity in MDS pathogenesis
de réir: David A. Sallman, et al.
Foilsithe / Cruthaithe: (2019-06-01)

High-risk MDS after HMAs
de réir: Lionel Adès
Foilsithe / Cruthaithe: (2019-06-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
de réir: S. Okabe, et al.
Foilsithe / Cruthaithe: (2022-06-01)

IMPLICATIONS OF NOVEL CLASSIFICATIONS OF MYELOID NEOPLASMS FOR CHILDHOOD MDS
de réir: Katherine R. Calvo
Foilsithe / Cruthaithe: (2023-12-01)

DHPLC analysis of the ATRX gene in myelodysplastic syndrome (MDS) associated with acquired alpha thalassemia (AT-MDS): Novel mutation detection despite somatic mosaicism.
de réir: Steensma, D, et al.
Foilsithe / Cruthaithe: (2003)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
de réir: Amer M. Zeidan, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Application of constacyclic codes to quantum MDS codes
de réir: Chen, Bocong, et al.
Foilsithe / Cruthaithe: (2015)

A construction of MDS quantum convolutional codes
de réir: Zhang, Guanghui, et al.
Foilsithe / Cruthaithe: (2015)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
de réir: Mohd Tohit, Eusni Rahayu, et al.
Foilsithe / Cruthaithe: (2012)

On linear codes whose hermitian hulls are MDS
de réir: Luo, Gaojun, et al.
Foilsithe / Cruthaithe: (2024)

HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
de réir: Mazyar Shadman, et al.
Foilsithe / Cruthaithe: (2014-09-01)

Value-based adoption of MDS:an empirical investigation
de réir: ZHOU Yi1, et al.
Foilsithe / Cruthaithe: (2008-01-01)

Editorial: MDS: new scientific and clinical developments
de réir: Sabine Blum, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Value-based adoption of MDS:an empirical investigation
de réir: ZHOU Yi1, et al.
Foilsithe / Cruthaithe: (2008-01-01)

Understanding iron homeostasis in MDS: the role of erythroferrone
de réir: Mohammed L. Abba, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Controversies on the Consequences of Iron Overload and Chelation in MDS
de réir: Francesca Vinchi, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Recent advances in MDS mutation landscape: splicing and signalling
de réir: Follo, MY, et al.
Foilsithe / Cruthaithe: (2019)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
de réir: Theo de Witte, et al.
Foilsithe / Cruthaithe: (2020-09-01)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
de réir: Adrian Mosquera-Orgueira, et al.
Foilsithe / Cruthaithe: (2023-08-01)

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
de réir: Malcovati, L, et al.
Foilsithe / Cruthaithe: (2020)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
de réir: A. DeZern, et al.
Foilsithe / Cruthaithe: (2022-06-01)

New Systematic MDS Array Codes With Two Parities
de réir: Lan Ma, et al.
Foilsithe / Cruthaithe: (2024-01-01)

MDS CODEC EVALUATION BASED ON PERCEPTUAL SOUND ATTRIBUTES
de réir: Marcelo Herrera Martínez, et al.
Foilsithe / Cruthaithe: (2014-12-01)